NCT06875128: An ongoing trial by Delcath Systems Inc.
This trial is ongoing. It must report results 4 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06875128 |
|---|---|
| Title | An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment With Melphalan/HDS Followed by Consolidation Treatment With Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients With Metastatic Breast Cancer With Liver Dominant Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 29, 2026 |
| Completion date | May 31, 2029 |
| Required reporting date | May 31, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |